Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma

BACKGROUND: We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal squamous cell carcinoma (ESCC) patients. METHODS: We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy numbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, H, Ichikawa, D, Komatsu, S, Tsujiura, M, Kosuga, T, Deguchi, K, Konishi, H, Morimura, R, Shiozaki, A, Fujiwara, H, Okamoto, K, Otsuji, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865765/
https://www.ncbi.nlm.nih.gov/pubmed/20389301
http://dx.doi.org/10.1038/sj.bjc.6605657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865765/
https://www.ncbi.nlm.nih.gov/pubmed/20389301
http://dx.doi.org/10.1038/sj.bjc.6605657

Ejemplares similares